Corporate &
Commercial Strategy

Corporate Advisory Portfolio & Franchise Strategy Asset Commercialization Strategy Development

Overview

Asymmetry Group designs and implements corporate, therapeutic area, and product strategies globally and locally. We utilize a rigorous “choice based” approach to facilitating leadership alignment on strategy, and directly link these choices to market-level execution. After all, if a strategy can’t be effectively implemented, it’s not the right strategy. Our strategic work drives organizational confidence in making disproportionate investments where the business is best suited to win.

Corporate Advisory

We partner with senior leaders to facilitate complex strategy discussions, develop corporate narratives and roadmaps, and serve as thought partners on long-range company strategy and foundational strategic choices.

Types of Projects:

Corporate Growth Strategy & Roadmap
Corporate Narrative Development
Business Model Definition

Case Study

Portfolio & Franchise Strategy

We help organizations think critically about prioritizing their early-stage portfolio (pre-clinical and early clinical), as well as developing comprehensive franchise strategies that optimize business outcomes when they have multiple assets in the same therapeutic area.

Types of Projects:

Market Opportunity Assessment
Portfolio Optimization & Indication Prioritization
Franchise Strategy Development

Case Study

Asset Commercialization Strategy Development

We practice an agile approach to developing strategy appropriate to the lifecycle stage of the asset, and are experienced in facilitating robust, cross-functional dialogue to drive organizational alignment and action on key strategic choices.

Types of Projects

Early Asset Valuation & Commercial Forecast Modeling
Early Commercial Strategy Development
Launch Strategy Development & Commercialization Planning

Case Study

Testimonials

"Thank you once again for leading a successful launch readiness meeting. The content, meeting design, and execution was extremely well done. I continue to be very impressed with the way you work and the support that you’re providing."

Kyle

Head of U.S. | Marketing

Emerging rare disease company

“I asked Asymmetry Group to create a cross-functional strategic plan for our ~$300M business. Greg and his team expertly drove new analytics to ground our strategic discussions, led challenging team discussions around where to focus our business and disproportionately invest, and ultimately created a clear multi-year plan that’s aligned across sales, marketing, market access and other functions. We now use this approach as the best practice in other therapeutic areas.”

Michelle

Vice President | Marketing

Multi-billion dollar specialty biopharma company

"What’s really impressive is how it really feels like our business is keeping the Asymmetry team up at night and they’re thinking ahead and considering stuff before we do – it’s a level of engagement and honestly caring that is unusual in team members let alone external partners! Cannot thank you enough b/\c it is so much more than the work but the spirit and caring that makes the difference."

Molly

General Manager | Marketing

Public rare disease company, launching first asset

"Thank you once again for leading a successful launch readiness meeting. The content, meeting design, and execution was extremely well done. I continue to be very impressed with the way you work and the support that you’re providing."

Kyle

Head of U.S. | Marketing

Emerging rare disease company

“I asked Asymmetry Group to create a cross-functional strategic plan for our ~$300M business. Greg and his team expertly drove new analytics to ground our strategic discussions, led challenging team discussions around where to focus our business and disproportionately invest, and ultimately created a clear multi-year plan that’s aligned across sales, marketing, market access and other functions. We now use this approach as the best practice in other therapeutic areas.”

Michelle

Vice President | Marketing

Multi-billion dollar specialty biopharma company

"What’s really impressive is how it really feels like our business is keeping the Asymmetry team up at night and they’re thinking ahead and considering stuff before we do – it’s a level of engagement and honestly caring that is unusual in team members let alone external partners! Cannot thank you enough b/\c it is so much more than the work but the spirit and caring that makes the difference."

Molly

General Manager | Marketing

Public rare disease company, launching first asset

"Thank you once again for leading a successful launch readiness meeting. The content, meeting design, and execution was extremely well done. I continue to be very impressed with the way you work and the support that you’re providing."

Corporate &
Commercial Strategy

Overview

Corporate Advisory

Types of Projects:

Portfolio & Franchise Strategy

Types of Projects:

Asset Commercialization Strategy Development

Types of Projects

Testimonials

Kyle

Head of U.S. | Marketing

Emerging rare disease company

Michelle

Vice President | Marketing

Multi-billion dollar specialty biopharma company

Molly

General Manager | Marketing

Public rare disease company, launching first asset

Hilary

Senior Director | Marketing

Global biopharmaceutical company

Kyle

Head of U.S. | Marketing

Emerging rare disease company

Michelle

Vice President | Marketing

Multi-billion dollar specialty biopharma company

Molly

General Manager | Marketing

Public rare disease company, launching first asset

Hilary

Senior Director | Marketing

Global biopharmaceutical company

Kyle

Head of U.S. | Marketing

Emerging rare disease company

Corporate & Commercial Strategy

Overview

Corporate Advisory

Types of Projects:

Portfolio & Franchise Strategy

Types of Projects:

Asset Commercialization Strategy Development

Types of Projects

Testimonials

Michelle

Vice President | Marketing

Multi-billion dollar specialty biopharma company

Corporate &
Commercial Strategy